StockTipsArenaBeta

BUY Dr. Reddy's Laboratories Limited — Vikas Salunkhe, Nirmal Bang Securities

BUYDr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories share price target & all analyst calls

byVikas Salunkhe, Nirmal Bang SecuritiesHorizon: NA (inferred Swing (≤2wk))23 Jun 2026via CNBC Awaaz.

Entry₹1,309.7Inferred
Target₹1,370
Total upside +4.60% (call closed)
Stop loss₹1,290-1.50% risk
Exit₹1,37029 Jun 2026, 9:20 am
Target hit+4.60%0.00%upside left
Follow Vikas Salunkhe for new calls(27% target hit, 130 closed calls)Get alertsWatch DRREDDY for new buy/sell callsGet alertsSee 4 active Swing calls on DRREDDY

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 26 Oct, 1:51 am IST
3 supporting0 opposing
Supports the BUY call (3)

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·25 Jun · 3d ago

Dr. Reddy's Laboratories Limited announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States.

NSE · Press Release·13 Jun · 2w ago

(opens in new tab)

Dr. Reddy's Laboratories Ltd. has launched Bosutinib Tablets 400mg.

BSE · Company Update·13 Jun · 2w ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Dr. Reddy's Laboratories

All analyst calls on Dr. Reddy's Laboratories

More from Vikas Salunkhe, Nirmal Bang Securities

Every call and its outcome